Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2024
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 January 2024
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2021
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 June 2024
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2024
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab (Imfinzi) with bevacizumab (Avastin) for high-risk adjuvant hepatocellular carcinoma [ID6146]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC